Replies to post #223815 on Biotech Values

[DewDiligence]

TNXP—Now we know the impetus for the buyback authorization:

https://globenewswire.com/news-release/2019/03/01/1745581/0/en/Tonix-Pharmaceuticals-Provides-Update-on-Tonmya-for-the-Treatment-of-Posttraumatic-Stress-Disorder.html

The U.S. Food and Drug Administration (FDA) notified the Company that the Breakthrough Therapy designation (BTD) granted for Tonmya for PTSD in December 2016 has been rescinded because interim analysis data on Tonmya from the HONOR study do not support the continuation of the BTD.

This PR came out 90 minutes after the other one. LOL